Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease
Authors: Subhash C. Gulati, Charles L. Bennett
Journal: Annals of Internal Medicine (1992)

Article1 February 1992Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin DiseaseSubhash C. Gulati, MD, PhD, Charles L. Bennett, MD, PhDSubhash C. Gulati, MD, PhDSearch for more papers by this author, Charles L. Bennett, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-3-177 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Excerpt▪ Objective: To determine the clinical and economic effects of granulocyte macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed or refractory Hodgkin disease.▪ Design: A randomized, double-blind, phase III clinical trial.▪ Setting: A tertiary referral center.▪ Patients: Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation.▪ Main Results:The 12 patients treated with GM-CSF, when compared with placebo recipients, had shorter periods of neutropenia (median duration of an absolute neutrophil count of less than 1000 cells/mm3, 16 days compared with 27 days; P = 0.02), shorter periods of platelet-transfusion dependency (median duration, 13.5 days compared with 21 days; P = 0.03), and shorter hospitalizations (median hospital stay, 32 days compared with 40.5 days; P = 0.004). Other clinical outcomes, such as frequency and severity of toxicities, development of pneumonia or infection, in-hospital death, and response rate were similar in the two groups. Actuarial long-term disease-free survival was 64% for patients treated with GM-CSF and 58% for patients who received placebo after 32 months of follow-up (P = 0.15). The group treated with GM-CSF had lower total charges after infusion of autologous marrow than the placebo group (median in-hospital charges, $39 800 compared with $62 500; P = 0.005) because of lower post-infusion charges for room and board, antibiotic therapy, transfusions, laboratory tests, and physical therapy visits.▸Conclusions:Administration of GM-CSF was associated with acceleration of myeloid and platelet recovery and was cost effective in the treatment of patients with relapsed Hodgkin disease who received intensive chemotherapy....References1. De Vita V, Hubbard S, and Longo D. Treatment of Hodgkin's disease. Monogr Natl Cancer Inst. 1990;10:19-28. Google Scholar2. Gulati S, Yahalom J, Whitmarsh K, Clarkson B, and Gee T. Factors affecting the outcome of autologous bone marrow transplantation. Ann Oncol. 1991;2(Suppl 1):51-5. CrossrefMedlineGoogle Scholar3. Gulati S, Yahalom J, and Portlock C. Autologous bone marrow transplantation. Curr Probl Cancr. 1991;15:1-35. MedlineGoogle Scholar4. Jones R, Piantadosi S, Mann R, Ambinder R, Seifter E, and Vriesendorp H. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's Disease. J Clin Oncol. 1990;8:527-37. CrossrefMedlineGoogle Scholar5. Jagannath S, Armitage J, Dicke K, Tucker S, Velasquez W, and Smith K. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's Disease. J Clin Oncol. 1989;7:179-85. CrossrefMedlineGoogle Scholar6. Gianni A, Bregni M, Siena S, Orazi A, Stern A, and Gondola L. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol. 1990;8:761-4. CrossrefMedlineGoogle Scholar7. Chesson B, Lacerna L, Leyland-Jones B, Sarosy G, and Wittes R. Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med. 1989;110:51-65. LinkGoogle Scholar8. Armitage J and Gale R. Bone marrow autotransplantation. Am J Med. 1989;86:203-6. CrossrefMedlineGoogle Scholar9. Nemunaitis J, Rabinowe S, Singer J, Bierman P, Vose J, and Freedman A. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-8. CrossrefMedlineGoogle Scholar10. Collins C, Mortimer J, and Livingston R. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer. 1989;63:228-32. CrossrefMedlineGoogle Scholar11. Philip T, Armitage J, Spitzer G, Chauvin F, Jagannath S, and Cahn J. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-8. CrossrefMedlineGoogle Scholar12. Takvorian T, Canellos G, Ritz J, Freedman A, Anderson K, and Mauch P. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987;316:1499-505. CrossrefMedlineGoogle Scholar13. Carella A, Congiu A, Gaozza E, Mazza P, Ricci P, and Visani G. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol. 1988;6:1411-6. CrossrefMedlineGoogle Scholar14. Phillips G, Wolff S, Herzig R, Lazarus H, Fay J, and Lin H. Treatment of progressive Hodgkin's disease with intensive chemoradiology and autologous bone marrow transplantation. Blood. 1989;73:2086-92. CrossrefMedlineGoogle Scholar15. Gianni A, Bregni M, Siena S, Villa S, Sciorelli G, and Ravagnani F. Rapid and complete hematopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol. 1989;7:139-48. CrossrefMedlineGoogle Scholar16. Demetri G and Griffin J. Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? J Clin Oncol. 1990;8:761-4. CrossrefMedlineGoogle Scholar17. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, and Tabbara I. Reduction by granulocyte colony stimulating factor of fever and neutropenia in patients with small cell lung cancer. N Engl J Med. 1991;325:164-70. CrossrefMedlineGoogle Scholar18. Antman K, Griffin J, Elias A, Socinski M, Ryan L, and Cannistra S. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy induced myelosuppression. N Engl J Med. 1988;319:593-8. CrossrefMedlineGoogle Scholar19. Gabrilove J, Jakubowski A, Scher H, Sternberg C, Wong G, and Grous J. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414-22. CrossrefMedlineGoogle Scholar20. Mortsyn G, Campbell L, Souza L, Alton N, Keech J, and Green M. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1:667-72. MedlineGoogle Scholar21. Groopman J, Mitsuyasu R, DeLeo M, Oette D, and Golde D. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987;317:593-8. CrossrefMedlineGoogle Scholar22. Brandt S, Peters W, Atwater S, Kurtzberg J, Borowitz M, and Jones R. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988;318:869-76. CrossrefMedlineGoogle Scholar23. Nemunaitis J, Singer J, Bucker C, Hill R, Storb R, and Thomas E. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation for lymphoid malignancies. Blood. 1988;72:834-6. CrossrefMedlineGoogle Scholar24. Redbook 1990. Oradell, New Jersey: Medical Economics Company; 1990. Google Scholar25. McCue J, Hansen C, and Gal P. Hospital charges for antibiotics. Rev Infect Dis. 1985:7:643-5. CrossrefMedlineGoogle Scholar26. Jacobs J and Wyant S. Economic examination of cefoperazone therapy. Drug Intell Clin Pharm. 1987;21:373-9. CrossrefMedlineGoogle Scholar27. Granulocyte colony-stimulating factors. Med Lett Drugs Ther. 1991;33:61 MedlineGoogle Scholar28. Welch H and Larson E. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 1989;321:807-12. CrossrefMedlineGoogle Scholar29. Welch H and Larson E. Rapid estimation of hospital charges in patients with leukemia. Validation of a multivariate prediction model. Med Care. 1989;27:900-4. CrossrefMedlineGoogle Scholar30. Kukull W, Koepsell T, Conrad D, Immanuel V, Prodzinski J, and Franz C. Rapid estimation of hospitalization charges from a brief medical record review. Evaluation of a multivariate prediction model. Med Care. 1986;24:961-6. CrossrefMedlineGoogle Scholar31. Finkler S. The distinction between cost and charges. Ann Intern Med. 1982;96:102-9. LinkGoogle Scholar32. Hannan E, O'Donnell J, Kilburn H J, Bernard H, and Yazici A. Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals. JAMA. 1989;262:503-10. CrossrefMedlineGoogle Scholar33. Bennett C, Gertler P, Guze P, Garfinkle J, Kanouse D, and Greenfield S. The relation between resource use and in-hospital mortality for patients with acquired immunodeficiency syndrome related Pneumocystis carinii pneumonia. Arch Intern Med. 1990; 150:1447-52. CrossrefMedlineGoogle Scholar34. Klingemann H, Eaves A, Onetto N, Wilkie-Boyd K, Barnett M, and Connors J. Randomized trial of GM-CSF (2 hour versus 24 hour infusion) after autologous bone marrow transplantation (AuBMT) for Hodgkin's disease. Exp Hematol. 1991;19:386. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Subhash C. Gulati, MD, PhD; Charles L. Bennett, MD, PhDFrom Memorial Sloan-Kettering Cancer Center, New York, New York; Duke University School of Medicine and Durham Veterans Affairs Hospital, Durham, North Carolina; and the RAND Corporation, Santa Monica, California. For current author addresses, see end of text. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disordersProphylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapyLipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteersCytokine networking of innate immunity cells: a potential target of therapyColony-Stimulating Factors for Febrile Neutropenia during Cancer TherapyPractice Guidelines for the Use of rHuG-CSF in an Oncology SettingModifications of Optical Properties of Blood during Photodynamic Reactions In vitro and In vivoThe Myeloid Growth FactorsProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyEvaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitisMeta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of InfectionLillian Sung, MD, PhD, Paul C. Nathan, MD, MSc, Shabbir M.H. Alibhai, MD, MSc, George A. Tomlinson, PhD, and Joseph Beyene, PhDAcute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant ChemotherapyBone Marrow and Peripheral Blood Stem Cell TransplantationMeta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell TransplantationEconomic Impact of Cancer in the United StatesGM-CSF — Biochemical purification and molecular and biologic characterizationEconomic aspects of high-dose chemotherapy: a clinician's perspective reviewHaemopoietic Growth Factors in Paediatric OncologyEvaluating the Financial Impact of Clinical Trials in Oncology: Results From a Pilot Study From the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges ProjectThe Use of Cytokines during Blood and Marrow TransplantationEconomic, Public Health, and Policy Implications of Hematopoietic Growth Factors, High-dose Chemotherapy, and Stem Cell RescueDevelopment of a Recombinant Growth Factor and Fusion Protein: Lessons from GM-CSFColony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropeniaGranulocyte-Macrophage Colony-Stimulating Factor (GM-CSF):Biology and Clinical StatusComparison of Cytokines in Children with Recurrent Solid Tumors Treated with Intensive ChemotherapyThe use of Granulocyte Colony-Stimulating Factors following Peripheral Blood Progenitor Cell Rescue after High-Dose Chemotherapy for Advanced Breast Cancer: A Prospective StudyA European perspective on haematopoietic growth factors in haemato-oncology: Report of an expert meeting of the EORTCÉvaluation économique de l'utilisation de facteurs de croissance hématopoïétiques dans la prise en charge des hémopathies malignesThe True Cost of Bone Marrow TransplantationThe True Cost of Bone Marrow TransplantationNeutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapyGranulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: Correlation with clinical responsesConsensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpointRecombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantationHealth care economics and bone marrow transplantationInitial Trial of PIXY 321 Following Autologous Bone Marrow TransplantationHematopoiesisEconomic Analyses of Phase III Cooperative Cancer Group Clinical Trials: Are They Feasible?Economic Analyses in Clinical Trials for Cooperative Groups: Operational ConsiderationsFacteurs de croissance et infectionClinical role of GM-CSF in neutrophil recovery in relation to health care parameters8 Treatment of relapsed Hodgkin's diseaseGranulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantationManagement of relapsed and refractory Hodgkin's diseaseEconomic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantationHOST IMMUNOLOGIC AUGMENTATION FOR THE CONTROL OF INFECTIONCost-effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatinCHEMOTHERAPY AND NEUTROPENIATHE THROMBOCYTOPENIA OF CANCERCOST-EFFECTIVENESS AND COST CONTAINMENTEconomic Implications of High Dose Chemotherapy Programs with Autologous Stem Cell SupportThe Experience of Polish Children’s Leukemia Lymphoma Study Group on G-CSF and GM-CSF Interventional Use in Neutropenia Associated with Chemotherapy of Childhood Acute Lymphoblastic Leukemia (ALL)Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?The photodecontamination of cellular blood components: Mechanisms and use of photosensitization in transfusion medicineGM-CSF Did Not Allow Doxorubicin Dose Escalation in the MAID Regimen: A Phase I Trial. A Southwest Oncology Group StudyClinical Needs for Hematopoietic Growth Factors: Old and NewRecombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma—a randomised pilot studyThe clinical-economic trial: Promise, problems, and challengesINFECTION IN THE BONE MARROW TRANSPLANT RECIPIENTCytokines in Stem Cell TransplantationEffects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow afEffects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous Done marrow afEffects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic FibrosisRecombinant growth factorsGranulocyte growth factors: Achieving a consensusEffects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study.Prophylactic administration of granulocyte colony‐stimulating factor (filgrastim) after conventional chemotherapy in children with cancerAllogeneic marrow transplantation and the use of hematopoietic growth factorsGranulocyte‐macrophage colony‐stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trialsHigh‐dose chemotherapy with stem cell reinfusion and growth factor support for solid tumorsRole of Haemopoietic Growth Factors in Lymphoma TherapyHigh-dose chemotherapy of solid tumoursHigh-Dose Chemotherapy of Metastatic Breast Cancer: A ReviewEconomic Analysis of Prophylactic G-CSF after Mini-BEAM Salvage Chemotherapy for Hodgkin's and Non-Hodgkin's LymphomaMarrow Transplantation for Hodgkin's Disease: Points to PonderEfficacy of Delayed Granulocyte Colony-Stimulating Factor after Full Dose CHOP Therapy in Non-Hodgkin's Lymphoma: A Pilot Study for a Leukocyte Count Oriented RegimenHodgkin's Disease: Basing Treatment Decisions on Prognostic FactorsEconomic Effect of Myeloid Growth Factors on Cancer TreatmentClinical Use of Hematopoietic Growth Factors for Control of Infections after High-Dose ChemotherapyEconomic study of neutropenia induced by myelotoxic chemotherapyBone marrow transplantation for acute lymphoblastic leukemia(all)Role of Colony-Stimulating Factors During High Dosage ChemotherapyG- and GM-CSF in oncology and oncological haematologyResults of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's diseaseFuture uses of granulocyte&hyphen;macrophage colony&hyphen;stimulating factor &lpar;GM&hyphen;CSF&rpar;Growth factors and hematopoietic recovery4 Cytokines acting on committed haematopoietic progenitorsGranulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral leishmaniasisBIOLOGICAL AND CLINICAL ASPECTS OF HEMATOPOIETIC STEM CELLSEconomic analyses of clinical trials in cancer: Are they helpful to policy makers?Intensive therapy and autotransplantation in hodgkin's diseaseDerzeitiger Stand der klinischen Anwendung von hämopoetischen Wachstumsfaktoren (G-CSF, GM-CSF) nach Chemo-/StrahlentherapieEfficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancerPeripheral Blood Progenitor Cell Transplantation: Clinical, Practical, and Economic ConsiderationsEconomic Analysis in Phase III Clinical Cancer TrialsGranulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remissionHigh-Intensity Chemotherapy with Hematopoietic Support in Breast CancerA Phase II Study of Methotrexate, Vinblastine, Doxorubicin and Cisplatin Plus Recombinant Human Granulocyte-Macrophage Colony Stimulating Factors in Patients with Advanced Transitional Cell CarcinomaRole of Autotransplantation in Hodgkin’s DiseaseBeneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trialSouthwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth FactorsGM‐CSF as an adjunct to autologous bone marrow transplantationTiming of bone marrow transplantation in therapy of Hodgkin’s diseaseTheoretical and Practical Considerations on the Use of Recombinant Human GM-CSF in TransplantationOpportunistic pneumoniaInterleukin-1: Biological Effects in Human HematopoiesisrhGM-CSF After Allogeneic Bone Marrow Transplantation From Unrelated Donors: A Pilot Study of Cyclosporine and Prednisone as Graft-Versus-Host Disease ProphylaxisGranulocyte-macrophage colony-stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatinGranulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorGM-CSF in Hodgkin DiseaseGeraldine P. Schechter, MDNewsGranulocyte-macrophage colony-stimulating factor (GM-CSF): what role in bone marrow transplantation?Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Answers or More Questions?Julie M. Vose, MD, Philip J. Bierman, MD, James O. Armitage, MDValuing Clinical Strategies Early in Their DevelopmentH. Gilbert Welch, MD, MPHThe use of colony stimulating factors in clinical bone marrow transplantationColony-Stimulating Factors: A New Step in Clinical Practice. Part I 1 February 1992Volume 116, Issue 3Page: 177-182KeywordsClinical trialsGranulocyte macrophage colony stimulating factorHealth services researchHematology and oncologyHodgkin lymphomaHospital medicinePatientsPlateletsPneumoniaToxicity ePublished: 1 December 2008 Issue Published: 1 February 1992 PDF downloadLoading ...